



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS

### Citation for published version:

Gedik, KC, Lamot, L, Romano, M, Demirkaya, E, Piskin, D, Torreggiani, S, Adang, LA, Armangue, T, Barchus, K, Cordova, DR, Crow, YJ, Dale, RC, Durrant, KL, Eleftheriou, D, Fazzi, E, Gattorno, M, Gavazzi, F, Hanson, EP, Lee-Kirsch, MA, Montealegre Sanchez, GA, Neven, B, Orcesi, S, Ozen, S, Poli, MC, Schumacher, E, Tonduti, D, Uss, K, Aletaha, D, Feldman, BM, Vanderver, A, Brogan, P & Goldbach-Mansky, R 2022, 'The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS', *Annals of the Rheumatic Diseases*. <https://doi.org/10.1136/annrheumdis-2021-221814>

### Digital Object Identifier (DOI):

<https://doi.org/10.1136/annrheumdis-2021-221814>

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

Annals of the Rheumatic Diseases

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



The 2021 EULAR and ACR points to consider for diagnosis and management of  
autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS

Kader Cetin Gedik<sup>\*1</sup>, Lovro Lamot<sup>\*2</sup>, Micol Romano<sup>\*3</sup>, Erkan Demirkaya<sup>3</sup>, David Piskin<sup>4,5</sup>,  
Sofia Torreggiani<sup>1,6</sup>, Laura A. Adang<sup>7</sup>, Thais Armangue<sup>8</sup>, Kathe Barchus<sup>9</sup>, Devon R. Cordova<sup>10</sup>,  
Yanick J. Crow<sup>11,12</sup>, Russell C. Dale<sup>13</sup>, Karen L. Durrant<sup>9,14</sup>, Despina Eleftheriou<sup>15</sup>, Elisa M.  
Fazzi<sup>16</sup>, Marco Gattorno<sup>17</sup>, Francesco Gavazzi<sup>7,18</sup>, Eric P. Hanson<sup>19</sup>, Min Ae Lee-Kirsch<sup>20</sup>, Gina  
A. Montealegre Sanchez<sup>21</sup>, Bénédicte Neven<sup>22</sup>, Simona Orcesi<sup>23,24</sup>, Seza Ozen<sup>25</sup>, M. Cecilia  
Poli<sup>26</sup>, Elliot Schumacher<sup>9</sup>, Davide Tonduti<sup>27</sup>, Katsiaryna Uss<sup>1</sup>, Daniel Aletaha<sup>28</sup>, Brian M.  
Feldman<sup>29,30,31</sup>, Adeline Vanderver<sup>7,32</sup>, Paul Brogan<sup>15</sup>, Raphaela Goldbach-Mansky<sup>1</sup>

\*Equally contributed

<sup>1</sup>Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and  
Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health,  
Bethesda, Maryland, USA.

<sup>2</sup>Department of Pediatrics, University Hospital Centre Zagreb, University of Zagreb School of  
Medicine, Zagreb, Croatia.

<sup>3</sup>Division of Paediatric Rheumatology, Department of Paediatrics, Schulich School of Medicine  
and Dentistry, University of Western Ontario, London, Ontario, Canada.

<sup>4</sup>Lawson Health Research Institute, London Health Sciences Center, London, Ontario, Canada.

<sup>5</sup>Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry,  
University of Western Ontario, London, Ontario, Canada.

<sup>6</sup>UOC Pediatria a Media Intensità di Cura, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

<sup>7</sup>Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

<sup>8</sup>Pediatric Neuroimmunology Unit, Neurology Service, Sant Joan de Deu Children's Hospital, and IDIBAPS-Hospital Clinic, University of Barcelona, Barcelona, Spain.

<sup>9</sup>Autoinflammatory Alliance, San Francisco, CA, USA.

<sup>10</sup>Aicardi-Goutieres Syndrome Americas Association, Manhattan Beach, California, USA.

<sup>11</sup>Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

<sup>12</sup>Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Université de Paris, Paris, France.

<sup>13</sup>Kids Neuroscience Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

<sup>14</sup>Kaiser San Francisco Hospital, San Francisco, California, USA.

<sup>15</sup>University College London Great Ormond Street Institute of Child Health, London, United Kingdom.

<sup>16</sup>Child Neurology and Psychiatry Unit, Department of Clinical and Experimental Sciences ASST Civil Hospital, University of Brescia, Brescia, Italy.

<sup>17</sup>Center for Autoinflammatory diseases and Immunodeficiencies, IRCCS G. Gaslini, Genoa, Italy.

<sup>18</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

<sup>19</sup>Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA.

<sup>20</sup>Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

<sup>21</sup>Intramural Clinical Management and Operations Branch (ICMOB), Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

<sup>22</sup>Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Imagine, Paris, France.

<sup>23</sup>Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.

<sup>24</sup>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

<sup>25</sup>Pediatric Rheumatology, Hacettepe University, Ankara, Turkey.

<sup>26</sup>Department of Pediatrics, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.

<sup>27</sup>Child Neurology Unit, COALA (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, Milano, Italy.

<sup>28</sup>Department of Rheumatology, Medical University of Vienna, Vienna, Austria.

<sup>29</sup>Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada.

<sup>30</sup>Department of Pediatrics, Faculty of Medicine, Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.

<sup>31</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

<sup>32</sup>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Corresponding author:

Raphaëla Goldbach-Mansky, MD, MHS

Translational Autoinflammatory Diseases Section (TADS)

Laboratory of Clinical Immunology and Microbiology, LCIM, NIAID/NIH

Bldg.10, MSC1960

10 Center Dr.

Bethesda, MD 20892

e-mail: goldbacr@mail.nih.gov

Word Count: 6604

Keywords: type I interferonopathies; CANDLE; PRAAS; SAVI; AGS

## ABSTRACT

**Objective:** Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature / proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) are rare, and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of “points to consider” to improve diagnosis, treatment, and long-term monitoring of patients with these rare diseases.

**Methods:** Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates, and an allied health care professional, formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires, and consensus methodology, “points to consider” to guide patient management were developed.

**Results:** The Task Force devised consensus and evidence-based guidance of four overarching principles and 17 points to consider regarding the diagnosis, treatment, and long-term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI, and AGS.

**Conclusion:** These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treatment, and management of patients with CANDLE/PRAAS, SAVI and AGS and aim to standardize and improve care, quality of life, and disease outcomes.

## INTRODUCTION

Autoinflammatory type I interferonopathies are genetically defined (monogenic or digenic) immunodysregulatory disorders characterized by the presence of a type I interferon (IFN) signature in peripheral blood, and variable systemic inflammation.<sup>1-3</sup> In this expanding group of

ultra-rare diseases, the most common are chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature / proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) are the most common.

Patients with type I interferonopathies present early in life often within the first week of life; prenatal onset has been reported in AGS patients; however, late-onset cases presenting at ages 14, 18 and 5.6 years with CANDLE/PRAAS, SAVI and AGS respectively have been reported.<sup>4-11</sup> Despite CANDLE/PRAAS, SAVI and AGS having distinct clinical phenotypes of varying disease severity, their individual clinical manifestations of these diseases can overlap, and all are associated with high morbidity and mortality if untreated.<sup>4 12</sup> Recent advances in the genetic description of these disorders permit better characterization of disease-specific clinical manifestations, and provide evidence supporting the pathogenic role of type I IFN signaling.<sup>1 2 12</sup><sup>13</sup> These developments prompted the Task Force lead by the steering committee (two convenors [PB, RGM], a neurologist [AV], two methodologists [BF, ED] and three pediatric rheumatologists/EULAR fellows [KCG, LL, MR] and a rheumatologist [ST]) to review the existing data, and develop consensus statements, with the aim of formulating state-of-the-art guidance on the diagnosis, treatment and long-term monitoring of patients with these rare diseases.

Thus, the objective of this project was to develop points to consider for the diagnosis, treatment, and long-term monitoring of patients with CANDLE/PRAAS, SAVI and AGS.

The Task Force targets their guidance to pediatricians, internists, and subspecialists involved in the care of patients with autoinflammatory type I interferonopathies and to patients and caregivers. These points to consider were developed not only to provide a resource for physicians to facilitate management, but also for policy makers governing who have a role in

authorizing patients' access to various diagnostic tools and treatment options; all with the ultimate goal to harmonize the level of care, and to improve quality of life and disease outcomes in this patient population.

## **METHODS**

The European Alliance of Rheumatology Associations (EULAR)<sup>14</sup> and the American College of Rheumatology (ACR) standardized operating procedures (SOPs) were followed during the project period (see online supplementary methods). With approval from the EULAR and ACR Executive Committees, an international Task Force consisting of worldwide recognized experts from North America, South America, Europe, and Australia convened to develop points to consider for the diagnosis, treatment, and long-term monitoring of three type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. The Task Force members were selected based on expertise in treatment and care of these patients.

A face-to-face meeting in August 2019 defined the goal of the project and the target population. Then, the Task Force developed research questions related to diagnosis, treatment and long-term monitoring of these diseases using the Population, Intervention, Comparison, Outcome (PICO) format. Search terms were derived from PICO questions and a systematic literature review (SLR) was performed by three research fellows (KCG, MR, LL), with support from a librarian and an epidemiologist (DH and DP), and a senior methodologist (ED) to identify relevant literature published before September 2020.

Two rounds of pre-consensus meeting questionnaires, using the Delphi technique,<sup>15</sup> included questions pertaining to diagnosis, treatment and long-term monitoring were sent to all Task Force members to indicate their agreement with each question or statement with yes/no using



the Delphi technique; the Delphi questionnaire was sent to 28 Task Force Members of who 22 were voting members. The Task Force members were asked to indicate their agreement with each statement, and a free text option was provided to capture every member's comment for each statement. Draft statements and items in questions with 80% or higher agreement were retained for voting at the consensus meetings. Statements and items questions that did not reach a greater than 80% consensus were reviewed and re-worded and sent out in a second round of the Delphi questionnaire. The original and the revised/modified draft statements with the previously achieved level of agreement and the participants' comments were included in the second survey. A free text option to capture comments and additional items was again included. Draft statements with 80% or higher agreement were retained for voting at the consensus meetings, and statements, that did not achieve 80% agreement, were marked for further discussion and refinement at the two consensus meetings. Responses were anonymous.

Based on the SLR findings and two pre-consensus meeting Delphi questionnaires, draft statements were refined by the steering group and were sent to the voting members prior to the consensus meetings. These draft statements were reviewed, discussed, revised, and voted on in two consensus meetings, that were held online in October 2020 due to the coronavirus disease 2019 (COVID-19) pandemic, one for CANDLE/PRAAS and SAVI, and one for AGS.

Two conveners (RGM, PB), three methodologists (BF, ED, DA), three fellows, an allied health professional, and three disease experts attended both consensus meetings and, otherwise, participation was based on disease specific expertise. The voting panel included 19 experts, one allied health professional and one patient representative for each disease. The joint statements addressing all three interferonopathies were voted on by the entire voting panel; CANDLE/SAVI specific statements were voted on by 10 experts, one allied health professional, one SAVI and one

CANDLE patient representative, and AGS specific statements were voted on by 14 experts, one allied health professional and one AGS patient representative. During the meetings, statements that achieved at least 80% agreement were accepted; statements with <80% were discussed a final time in a Nominal Groups round robin discussion (<https://www.cdc.gov/healthyyouth/evaluation/pdf/brief7.pdf>) and were only accepted if the revised statement reached an 80% agreement.

The Oxford Levels of Evidence (LoE) were applied to each point to consider.<sup>16</sup> The strength of each statement ranged from A (directly based on level I evidence) to D (directly based on level IV evidence or extrapolated recommendations from level I, II or III evidence).<sup>16</sup> Finally, the finalized statements were circulated in a post-consensus meeting Delphi questionnaire to determine level of agreement (LoA). Members of the Task Force were asked to provide their final LoA for each point to consider using a scale of 0 (completely disagree) to 10 (completely agree), which is reported in the tables below.

## **RESULTS**

### **Systematic literature review**

A summary of the literature search strategy and results are provided as supplementary material (online supplementary methods). Based on SLR and consensus conferences, four overarching principles and 17 disease-specific points to consider pertaining to the genetically defined interferonopathies (table 1) with their respective LoE, grade of recommendation (GoR), and LoA were generated.<sup>17</sup>

**Table 1 Points to consider for the diagnosis, treatment, and long-term monitoring of patients with type I interferonopathies, CANDLE/PRAAS, SAVI and AGS**

		LoE/GoR	LoA (mean ± SD)
<b>Overarching principles</b>		<b>C/S/AGS</b>	
<b>A</b>	Patients with autoinflammatory interferonopathies CANDLE/PRAAS, SAVI or AGS present with chronic systemic and organ-specific inflammation; when untreated, chronic inflammation results in progressive organ damage, early morbidity, and increased mortality.	4C/4C/4C	9.8±0.7
<b>B</b>	A confirmed genetic diagnosis is required to make the diagnosis of CANDLE/PRAAS, SAVI and AGS, which facilitates initiation of targeted treatments, genetic counselling, screening for complications, and informs prognosis.	5D/5D/4C	9.5±1.0
<b>C</b>	The goal of treatment of type I interferonopathies is to reduce systemic and organ inflammation to prevent or limit the development of and/or the progression of organ injury and damage, and to improve quality of life.	2B/2B/2B	9.8±0.5
<b>D</b>	In CANDLE/PRAAS, SAVI or AGS, long-term monitoring of disease activity, organ-specific injury/damage and of treatment related complications is required and involves a multi-disciplinary team.	5D/5D/4C	9.9±0.3
<b>Individual points to consider</b>			
<b>I.</b>	<b>Points to consider for diagnostic evaluation</b>		
<b>1</b>	Patients presenting with unexplained systemic inflammation (including elevations of CRP, ESR and/or an IFN signature) and clinical features* that include rashes, lipodystrophy, musculoskeletal, neurologic, pulmonary, and metabolic findings should receive a prompt diagnostic work up for CANDLE/PRAAS, SAVI and AGS comprising: <ul style="list-style-type: none"> <li>• genetic evaluation</li> <li>• clinical evaluation focusing on the extent of inflammatory organ involvement</li> <li>• screening for disease-related comorbidities</li> </ul>	4C/4C/4C	9.8±0.7
<b>2</b>	Patients with clinical symptoms of CANDLE/PRAAS, SAVI or AGS who do not carry any of the disease-causing mutations described here should be referred to specialty/research centers that can guide further work up and treatment.	5D/5D/5D	9.8±0.5
<b>Genetic evaluation</b>			
<b>3</b>	Mutations in the following disease-causing genes should be included in the genetic analyses: <ul style="list-style-type: none"> <li>• CANDLE/PRAAS: <i>PSMB8</i>, <i>PSMA3</i>, <i>PSMB4</i>, <i>PSMB9</i>, <i>PSMB10</i>, <i>POMP</i>, and <i>PSMG2</i>.</li> <li>• SAVI: <i>STING1</i> (previously <i>TMEM173</i>).</li> <li>• AGS: <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADARI</i>, <i>IFIH1</i>, <i>LSM11**</i> and <i>RNU7-1**</i>.</li> </ul>	4C/4C/4C	9.8±0.6
<b>4</b>	Genetic mimics of CANDLE/PRAAS, SAVI and AGS are recognized and should be included in the diagnostic work up (a non-exhaustive list is below for reference): <ul style="list-style-type: none"> <li>• for CANDLE-like conditions: Splice variants in <i>IKBKKG</i>, frameshift mutations in <i>SAMD9L</i>, and recessive mutations in <i>RNASEH2 (A, B, C)</i>.</li> <li>• for SAVI-like conditions: <i>TREX1</i>, <i>ADA2</i> and <i>COPA</i>.</li> <li>• for AGS-like conditions: <i>RNASET2</i>.</li> </ul>	4C/4C/4C	9.4±0.9
<b>Clinical evaluation (see also table 3)</b>			

5	In patients with suspected CANDLE/PRAAS, SAVI or AGS, assessment for disease and treatment related comorbidities should include screening for: <ul style="list-style-type: none"> <li>• <i>Skin manifestations</i>: nodular rashes, violaceous annular rashes, panniculitis, lipodystrophy or vasculopathic skin lesions.</li> <li>• <i>Neurological manifestations</i>: intracerebral calcifications, leukoencephalopathy, progressive microcephaly, or cerebral atrophy.</li> <li>• <i>Pulmonary manifestations</i>: interstitial lung disease/pulmonary hypertension.</li> <li>• <i>Hepatic manifestations</i>: hepatic steatosis, hepatitis, hepatosplenomegaly.</li> <li>• <i>Metabolic manifestations</i>: hypertension, hyperlipidemia, glucose intolerance (=metabolic syndrome).</li> <li>• <i>Musculoskeletal manifestations</i>: arthritis, contractures, and myositis.</li> <li>• <i>Growth and development</i>: growth retardation, osteoporosis, bone development delay, pubertal delay.</li> <li>• <i>Hematologic manifestations</i>: cytopenias (e.g., more specifically lymphopenia, thrombocytopenia).</li> <li>• <i>Ophthalmologic manifestations</i>: Episcleritis, keratitis, retinopathy, glaucoma.</li> <li>• <i>Cardiac manifestations</i>: Cardiomyopathy.</li> </ul>	4C/4C/4C	9.7±0.6
6	Neuroimaging should be performed in individuals with suspected neurologic symptoms. <ul style="list-style-type: none"> <li>• MRI best identifies white and grey matter changes.</li> <li>• CT is generally more sensitive for detecting cerebral calcification and can be considered when calcium sensitive modalities on MRI are not available or do not detect calcifications.</li> </ul>	4C/4C/4C	9.8±0.4
7	In patients with presumed CANDLE/PRAAS, SAVI or AGS, tissue sampling as appropriate (e.g., CSF if neurologic involvement is suspected, or lesional skin biopsies) may support the diagnosis.	4C/4C/4C	9.4±1.1
8	All patients should undergo a basic immunodeficiency work up that includes a history of infections, lymphocyte subsets and immunoglobulin levels, as a minimum.	4C/4C/4C	9.3±1.5
<b>II. Points to consider for treatment</b>			
9	Treatment of patients with CANDLE/PRAAS, SAVI and AGS should be aimed at achieving disease control or low disease activity to prevent progression of organ damage. For SAVI and CANDLE patients, disease control should be maintained with the lowest possible dose of glucocorticoids).	2B/2B/2B 4C/4C/NA	9.4±1.2
10	Janus Kinase inhibitors (JAKI) are of benefit for improving symptoms*** in CANDLE/PRAAS, SAVI, and AGS.	2B/2B/2B	9.3±0.9
11	In patients with CANDLE/PRAAS, SAVI or AGS on JAKI, screening for treatment-related comorbidities is important. We currently recommend monitoring for BK viral loads in urine and blood to prevent viral organ injury such as nephropathy.	4C/4C/5D	9.3±1.6
12	Glucocorticoids are of benefit for improving symptoms*** in CANDLE/PRAAS or SAVI. Chronic glucocorticoids do not improve the neurological features of AGS although acute courses of glucocorticoids may be useful for the treatment of non-CNS inflammatory conditions.	4C/4C/5D	9.0±1.3
<b>III. Points to consider for long-term monitoring and management</b>			
<i>Disease related comorbidities and disease progression</i>			

13	A multidisciplinary management team is required for optimal care of patients with CANDLE/PRAAS, SAVI and AGS, that is customized based on patient's disease manifestations.	5D/5D/5D	9.9±0.3
14	Disease activity and burden of disease should be monitored regularly depending on disease activity and severity (see table 3). <ul style="list-style-type: none"> <li>Symptom control can be monitored by assessing disease-specific symptoms*** using validated patient reported outcome and quality of life assessments, and by recording missing school or workdays.</li> </ul>	5D/5D/5D	9.3±1.8
15	Growth and development of children should be monitored at each visit.	5D/5D/5D	9.8±0.4
<b>Risk of COVID-19</b>			
16	At the time of writing there is no evidence to suggest that risks to patients with CANDLE/PRAAS, SAVI or AGS of COVID-19 are any different from the healthy population. Therefore, treatment for interferonopathy should not be stopped unless a specific contraindication to ongoing treatment arises.	5D/5D/5D	9.5±0.8
<b>Vaccinations</b>			
17	Generally, for CANDLE/PRAAS and SAVI all routine vaccines (live and killed) are indicated when not receiving immunosuppressive treatments or glucocorticoids, although this should be considered on a case-by-case basis.	5D/5D/5D	9.4±0.9

GoR: A: based on consistent level 1 studies; B: based on consistent level 2 or 3 studies or extrapolations from level 1 studies; C: based on level 4 studies or extrapolations from level 2 or 3 studies; D: based on level 5 studies or on troublingly inconsistent or inconclusive studies of any level.

LoE: 1a: systematic review of randomized controlled trials (RCTs); 1b: individual RCT; 2a: systematic review of cohort studies; 2b: individual cohort study (including low-quality RCT); 3a: systematic review of case-control studies; 3b: individual case-control study; 4: case-series (and poor-quality cohort and case-control studies); 5: expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'.

LoE and GoR are reported separately for each disease.

\*Disease-characteristic clinical features are listed in online supplementary table 4.

\*\*These two genes were published after the consensus meeting occurred.

\*\*\*Clinical symptoms are listed in Table 3 and Supplementary Table 4.

AGS, Aicardi-Goutières Goutières syndrome; CANDLE/PRAAS, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome; C/S/AGS: CANDLE/PRAAS/SAVI/AGS; CNS, central nervous system; COVID-19, Coronavirus disease 2019; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computerized tomography; ESR, erythrocyte sedimentation rate; GoR, grade of recommendation; IFN, interferon; JAKI, Janus kinase inhibitors; LoA, level of agreement; LoE, level of evidence; MRI, magnetic resonance imaging; NA, not applicable; SAVI, STING-associated vasculopathy with onset in infancy; SD, standard deviation.

## Overarching principles guiding the management of patients with CANDLE/PRAAS, SAVI and AGS

The systemic inflammatory multiorgan involvement in patients with CANDLE/PRAAS, SAVI or AGS can ultimately result in progressive organ injury and early mortality.<sup>4</sup> Damage accrues over

time, often manifesting later in life, thus highlighting the importance of early diagnosis and treatment.<sup>1 12</sup>

Autoinflammatory syndromes may present with phenotypic overlap early in life, which poses diagnostic challenges.<sup>12</sup> In addition, mutations in individuals genes may be associated with considerable phenotypic heterogeneity and variable disease severity.<sup>18 19</sup> Genetic confirmation is thus essential for making a precise diagnosis which then facilitates targeted therapy and initiation of genetic counseling with the goal to achieve better clinical outcomes. Patients, their parents, and siblings should have access to formal genetic counselling. Genetic counseling can initiate the risk assessment process depending on the type of inheritance for specific disease-causing mutation and help patients understand their test results, including the medical implications for themselves, their reproductive health concerns, and impact on their relatives. Patients with clinical symptoms of CANDLE/PRAAS, SAVI or AGS who do not harbor any of the disease-causing mutations described here should be referred to specialty/research centers that can guide further work up and treatment. There is no cure for type I interferonopathies. Current treatment options therefore aim to prevent development or progression of end organ damage by controlling systemic and organ inflammation,<sup>20 21</sup> to improve quality of life and to improve disease outcomes.<sup>1</sup> Given the paucity of long-term outcome data on newly available treatments, monitoring of disease activity, and development of organ-specific and treatment-related complications is essential.<sup>1 22 23</sup> A multi-disciplinary team is required to provide optimal care in the context of multiorgan system involvement.<sup>24 25</sup>

**Points to consider 1-8: Diagnostic evaluation focuses on raising an early suspicion and on facilitating genetic testing, appropriate clinical and laboratory work up and early treatment**

Diagnostic evaluation

The presence of a chronically elevated peripheral blood IFN signature is a common finding in patients with the type I interferonopathies CANDLE/PRAAS, SAVI and AGS. In contrast, traditional inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically elevated in CANDLE/PRAAS and SAVI but rarely in patients with AGS.<sup>2</sup>

<sup>7 12 18 26-30</sup> A peripheral blood IFN signature may be measured using different methodologies, including a 28-gene IFN scoring system using NanoString technology or by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR) methods of gene subsets should be measured repeatedly to establish chronic elevation.<sup>13</sup> Scores may be negative in the diagnostic phase in patients with milder disease; or in response to glucocorticoid treatment. In addition, patients with AGS with *RNASEH2B* mutations may have a negative IFN signature even with active disease.<sup>31</sup>

A practical barrier is the limited number of centers with the ability to check an IFN signature. Thus, a chronically elevated peripheral blood IFN signature is not required for diagnosis but can be very useful in raising the suspicion of an interferonopathy. For most IFN signatures, sensitivity and specificity data are not available. However, in a retrospective study, the IFN signature at a set cut-off score was helpful in differentiating patients with an interferonopathy from healthy controls and from patients with a cryopyrin associated periodic syndrome (an interleukin-1 mediated autoinflammatory disease). The IFN signature demonstrated an area under the receiver operator characteristic (ROC) curve of 0.98, with sensitivity and specificity exceeding 0.8.<sup>12</sup> Currently, the IFN signature should be interpreted in the context of normal values of the laboratory that conducts

the test, since no internationally standardized methodologies or reference ranges are currently available.

## Genetic evaluation

As there can be significant overlap of clinical features across several autoinflammatory disorders, a confirmed genetic diagnosis is critical to facilitating a precision medicine approach and targeted therapy. Next generation sequencing (e.g., targeted gene panel, whole exome, or whole genome sequencing) to screen for pathogenic variants rather than single gene Sanger sequencing is recommended. Sanger sequencing of individual genes may still be cost effective in patients with known familial disease; and may be the only available option if next generation sequencing is not yet available to the patient. However, this increasingly outdated “gene by gene” approach ultimately may result in diagnostic delay and may not be cost-effective.<sup>32</sup> In addition to the known disease-causing genes<sup>1 2 5 7 12 18 31 33-39</sup> (table 1), screening should be considered for diseases that can mimic one of these disorders; their genetic causes<sup>8 12 40-45</sup> are listed in table 2. Allelic, monogenic or digenic, double heterozygous mutations in genes encoding proteasome or immunoproteasome subunits are the cause for CANDLE/PRAAS with biallelic pathogenic *PSMB8* variants being the most common cause. Digenic disease causing mutations including *PSMB8*, *PSMA3*, *PSMB4* and *PSMB9*<sup>1 2 26</sup>, compound heterozygous mutations including *PSMB4*, *PSMB8* and *PSMG2*<sup>2 12</sup> and autosomal dominant loss-of-function mutations in *POMP*<sup>2</sup> also cause CANDLE/PRAAS but are rarer. However, novel disease-causing genes are being added as causes for CANDLE/PRAAS. All proteasome genes should be specifically assessed in a patient with a suggestive clinical phenotype. Both parents may need to be tested to confirm digenic inheritance. The inheritance of SAVI is mostly autosomal dominant, and most patients harbor a de novo



heterozygous missense mutations in the *STING1* gene that confers a gain-of-function in activating the IRF3 and *IFNB1* transcription.<sup>7 46</sup> Liu et al. also reported somatic mosaic mutations in one patient (OMIM-615934). So far only additive *STING1* gain-of-function mutations in p.R284W require homozygosity to confer disease.<sup>47</sup> Furthermore, mostly loss-of-function mutations in genes encoding proteins that regulate nucleic acid metabolism or signaling cause AGS.<sup>34</sup> These include biallelic null mutations in *TREX1* and *SAMHD1*; biallelic null mutations in the disease-causing genes, *RNASEH2A*, *RNASEH2B*, *RNASEH2C* or *ADARI* have not been reported. Disease-causing *IFIH1* variants are all heterozygous gain-of-function mutations that increase IFN signaling.<sup>34</sup> Recently, biallelic mutations in *LSM11* and *RNU7-1*, which encode components of the replication-dependent histone pre-mRNA-processing complex extend defects in nucleic acid metabolism to histone mRNAs.<sup>48</sup> It is important to notice that large deletions, such as deletions in AGS related genes including *SAMHD1*, may be missed on exome sequencing and need to be reviewed using other testing modalities.<sup>31 49 50</sup> If following routine genetic work up, a molecular diagnosis is not established in a patient with suggestive phenotypic features, referral to a research center of excellence for further evaluation should be considered.

<b>Table 2 List of genetically defined disease and genes that should be considered in the differential diagnosis of CANDLE/PRAAS, SAVI and AGS</b>	
<b>Genetically defined diseases*</b>	<b>Genes</b>
<b>CANDLE/PRAAS mimics/overlaps</b>	
<i>Differential diagnoses:</i>	
<ul style="list-style-type: none"> <li>▪ NEMO Deleted exon 5 Autoinflammatory Syndrome (NEMO-NDAS)</li> <li>▪ SAMD9L associated autoinflammatory disease (SAAD)</li> <li>▪ Other</li> </ul>	<i>IKBKG</i> (exon 5 deletion/splice variant)  <i>SAMD9L</i> (frame shift mutations) <i>RNASEH2B</i>
<b>SAVI mimics/overlaps</b>	
<i>Differential diagnoses:</i>	
<ul style="list-style-type: none"> <li>▪ Deficiency of the enzyme adenosine deaminase 2 (DADA2)</li> <li>▪ Familial chilblain lupus (CHBL)</li> <li>▪ COPA syndrome</li> </ul>	<i>ADA2</i> <i>TREX1</i> , <i>SAMHD1</i> <i>COPA</i>
<b>AGS mimics/overlaps</b>	
<i>Differential diagnoses:</i>	
<ul style="list-style-type: none"> <li>▪ Other</li> </ul>	<i>RNASET2</i>

## Other disorders with partially overlapping phenotypes

### *Differential diagnoses:*

▪ Spondyloenchondrodysplasia (SPENCD)	<i>ACP5</i>
▪ Singleton Merten syndromes	<i>IFIH1, DDX58</i>
▪ Retinal vasculopathy with cerebral leukodystrophy (RVCL)	<i>TREX1</i>
▪ Trichohepatoenteric syndrome (THES)	<i>TTC37, SKIV2L</i>
▪ Lipopolysaccharide responsive and beige-like anchor protein (LRBA) deficiency	<i>LRBA</i>
▪ Monogenic early onset lupus	e.g., <i>C1Q (A, B, C)</i> , several other

\*Based on current evidence, all type I interferonopathies, including but not limited to the genetically defined diseases listed in the table should be considered in the differential diagnosis of CANDLE/PRAAS, SAVI or AGS because of overlapping clinical and laboratory features.

AGS, Aicardi-Goutières syndrome; CANDLE/PRAAS, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome; SAVI, STING-associated vasculopathy with onset in infancy.

## Clinical evaluation

In patients with undifferentiated autoinflammatory diseases or otherwise unexplained systemic inflammation, certain clinical features are suggestive of CANDLE/PRAAS, SAVI or AGS (table 1 and online supplementary table 4). The following clinical features are relevant to the work up of patients with suspected interferonopathies:

### *Cutaneous manifestations*

Inflammatory skin lesions are present in all three diseases; however, the nature of the rash differs. Nodular rashes or violaceous annular rashes should prompt a diagnostic work-up for CANDLE/PRAAS. Another specific cutaneous finding for CANDLE/PRAAS is panniculitis (particularly neutrophilic panniculitis) and panniculitis induced lipodystrophy, which are hallmarks of the disease.<sup>1 2 9 12 18 36 37 51</sup>

The presence of vasculopathic skin lesions (e.g., pernio (“chilblain lesions”) or acral ischemia, ) is suggestive of SAVI<sup>44</sup> and AGS.<sup>33 52-55</sup> Skin involvement is the most common symptom in patients with SAVI at presentation<sup>1 7 56-59</sup> but some patients can present with severe lung disease and only minimal skin involvement.<sup>8 46 60 61</sup>

In addition to chilblain-like lesions and acrocyanosis, other skin manifestations such as periungual erythema, or necrotic lesions of the toes, fingers, and outer helix, can be seen in AGS patients.<sup>33 52-55</sup> Moreover, some AGS patients can have panniculitis as well.<sup>34</sup> Finally, some AGS patients have recurrent oral ulcers.<sup>50 62</sup>

Lesional skin biopsies in areas that can safely be biopsied can be beneficial in revealing the neutrophilic dermatosis, small vessel vasculitis (from necrotic area), fasciitis,<sup>57</sup> and granulomatous nodular dermatitis<sup>59</sup> thus supporting the diagnosis of SAVI while in AGS specifically, a lesional biopsy can demonstrate deposition of immunoglobulin and complement in the walls of small vessels.<sup>63</sup>

### *Neurologic manifestations*

Although CANDLE/PRAAS affected patients present with headaches and may develop aseptic meningitis,<sup>24</sup> neurologic findings are most common and severe in AGS and include subacute or acute neurologic decline, unexplained developmental delay, progressive microcephaly, dystonia, spasticity, encephalopathy, irritability and focal motor findings. A lumbar puncture typically shows sterile cerebrospinal fluid (CSF) pleocytosis.<sup>11 64 65</sup>

Neuroimaging should be performed in individuals with a suspected diagnosis of an interferonopathy in the presence of neurologic symptoms. The initial work up may include magnetic resonance imaging (MRI) of the brain which identifies best white and grey matter changes.<sup>41</sup> Computerized tomography (CT) head should be considered when calcium sensitive modalities on MRI are not available or not able to detect calcifications, since it is more sensitive for the detection of cerebral calcification.<sup>66</sup> Risks and benefits of sedating a child for MRI brain should be considered.<sup>67</sup> It is useful to have a baseline brain MRI to assess the severity and to

monitor disease associated complications; however, this is not a diagnostic prerequisite, especially for SAVI and CANDLE/PRAAS. Neuroimaging may be particularly helpful in patients with suspected AGS due to the dominant neurologic phenotype which should be differentiated from mimickers of interferonopathies.

Basal ganglia or other intracerebral calcifications are overlapping neuroimaging findings for all three diseases;<sup>68</sup> they are more common, more severe, and typically start earlier in life in patients with AGS compared with CANDLE/PRAAS, while calcifications are rare in SAVI.<sup>8 41 68</sup>  
<sup>69</sup> In addition, the presence of leukoencephalopathy is suggestive of AGS and typically starts early in life in AGS patients with severe disease; it is unusual in CANDLE/PRAAS or SAVI.<sup>11 70 71</sup>  
Other supportive neuroimaging characteristics for AGS are early and rapid cerebral atrophy with or without calcifications, cerebral white and gray matter changes, and Moyamoya disease.<sup>12 41 69 70</sup>  
<sup>72-74</sup> Intracerebral large vessel vasculitis or Moyamoya can be seen and is associated with *SAMHDI* mutations.<sup>49 74-77</sup>

Additional work up for neurodegenerative diseases in patients with suspected AGS may also be considered. Lumbar punctures are not required to make the diagnosis of AGS but may support the diagnosis<sup>72</sup> and characterize the immunologic features of the CNS inflammation, including the presence of lymphocytosis and raised levels of interferon-alpha (IFN- $\alpha$ ), CXCL10, and CCL2 in the CSF.<sup>31 54 69</sup> The CSF studies are most beneficial if a molecular diagnosis of AGS is not confirmed by genetic testing and provide support for additional molecular testing.<sup>72</sup>

### *Pulmonary manifestations*

The presence of early onset interstitial lung disease (ILD) raises suspicion for SAVI, in particular in the context of unexplained systemic inflammation.<sup>1 7 46 56 61</sup> Many patients with SAVI

are reported to have lung involvement, mostly manifested as ILD, ranging from mild ILD with no respiratory symptoms to lung fibrosis. Also, alveolar hemorrhage is reported as the presenting feature in a few cases with SAVI.<sup>47 60</sup> Although ILD is a major concern for patients with SAVI, it is rarely present in patients with CANDLE/PRAAS<sup>1 18 51</sup> and not reported in AGS. Low radiation chest CT and pulmonary function tests (PFTs) are recommended modalities to screen for ILD.<sup>8</sup> Lung biopsies may distinguish infectious from inflammatory disease but are not required to make the diagnosis of SAVI.<sup>7 46 60 61</sup>

Another significant pulmonary manifestation is pulmonary hypertension, which is a potentially life threatening and possibly underdiagnosed complication of CANDLE/PRAAS and AGS.<sup>1 12 78</sup> While CANDLE/PRAAS and AGS are known to affect the vascular system, the full impact of systemic vasculopathy is currently under-characterized. All patients with suspected CANDLE/PRAAS and AGS should undergo regular evaluation for pulmonary hypertension; echocardiography is recommended as a screening and monitoring tool.

### *Hepatic manifestations*

Forty to eighty percent of CANDLE/PRAAS patients develop metabolic syndrome and hepatic steatosis, often in the first decade of life.<sup>1</sup> In addition, patients may develop hepatosplenomegaly which could be due to extensive metabolic disturbance in fat processing.<sup>2 5 9 36 37 39 51</sup> In an open-label trial in CANDLE/PRAAS, it is reported that baricitinib did not significantly improve hepatic steatosis in two patients with hepatic steatosis prior to baricitinib treatment nor prevent it in three patients with hyperlipidemia at baseline pointing to the role of proteasome dysfunction in the etiology of hepatic steatosis.<sup>1</sup>

In AGS, hepatosplenomegaly and/or transaminitis can be an initial presentation in the neonatal period when it resembles congenital viral infection.<sup>31 33 72 79</sup> Later in life, patients can develop autoimmune hepatitis.<sup>34</sup>

Transaminases should be evaluated at presentation and may be monitored as a marker for hepatic disease activity in patients with type I interferonopathies, although it should be noted they can also be elevated in CANDLE/PRAAS and AGS due to myositis.<sup>12</sup>

Information about the clinical features of hepatic involvement in patients with SAVI is limited. However, case reports of patients with SAVI presenting with hepatic disease, such as necrotizing granulomatous hepatitis, cholestatic hepatitis and cholangitis and multiple biliary cysts are presented.<sup>58 80</sup>

### *Metabolic manifestation*

Metabolic abnormalities are significant concerns in patients with CANDLE/PRAAS and patients can develop metabolic syndrome defined by Ford et al. [presence of at least three of the following five criteria: hypertriglyceridemia  $\geq 110$  mg/dL, low high-density lipoprotein (HDL) cholesterol  $\leq 40$  mg/dL, abdominal obesity with waist circumference  $\geq 90^{\text{th}}$  percentile (sex specific), hyperglycemia  $\geq 110$  mg/dL, systolic or diastolic blood pressure  $\geq 90^{\text{th}}$  percentile (age, height, sex specific)].<sup>81</sup> In addition, these patients can have increased abdominal girth secondary to intra-abdominal fat deposition.<sup>1 51</sup> The work-up in CANDLE/PRAAS should include screening for metabolic abnormalities.

Patients with AGS may have hypothyroidism, often requiring replacement therapy, and insulin-dependent diabetes mellitus is reported.<sup>34 49 53 54 77 82-84</sup> Other endocrine manifestations include central diabetes insipidus, growth hormone deficiency and adrenal insufficiency.<sup>34 82</sup>

### *Musculoskeletal manifestations*

Myositis is a common feature of patients with CANDLE/PRAAS. It is usually patchy in distribution and can be demonstrated by muscle MRI.<sup>1 39 51</sup> In addition, most CANDLE/PRAAS patients will develop variable degrees of joint contractures in the hands and feet; these can be severely disabling.<sup>1 2 9 37 51</sup> Myopathy is described in individual case reports in AGS.<sup>85</sup> In AGS affected patients, joint involvement can include a lupus like arthritis, or progressive arthropathy with joint contractures.<sup>50 86 87</sup> Articular involvement in SAVI is seen in one third of the patients.<sup>8</sup> Rheumatoid factor (RF) positivity was reported in majority of cases (57%)<sup>8</sup> while anti-cyclic citrullinated peptide (anti-CCP) positivity was not common in patients with SAVI.<sup>7 43</sup> Interestingly, the course of the arthritis in SAVI can be destructive, especially in childhood, when associated with RF and anti-CCP antibodies.<sup>43</sup>

### *Growth and development*

Many children with chronic inflammation, including patients with type I interferonopathies, have lengths/heights and bone mineral density (BMD)s that are below that of age-matched controls. Height and BMD are further decreased in the context of treatment with glucocorticoids. Weight percentiles can increase sharply with high doses of glucocorticoids, and this should be taken into consideration when evaluating weight.<sup>1</sup>

In addition to abnormalities in stature, patients with AGS can have significant developmental delay; after a sub-acute onset most individuals develop profound neurologic regression and present with severe impairment in psychomotor development.<sup>22 23 34</sup> Patients with

AGS and CANDLE/PRAAS may also present with mild developmental delay;<sup>5 22 51</sup> these delays are not reported in patients with SAVI.<sup>8</sup>

### *Hematologic manifestations*

Cytopenias can occur in all three diseases due to temporary bone marrow suppression or homing changes and may correlate with disease activity.<sup>1 12</sup> Cytopenias including autoimmune cytopenias occur more frequently in CANDLE/PRAAS and AGS patients but are also seen in SAVI patients.<sup>1 8 18 33 50 52 54 60 79 82 88</sup> Thrombocytopenia in AGS patients can be present during the neonatal period mimicking congenital infection, but also later during the course of the disease associated with other hematologic abnormalities such as anemia and leukopenia.<sup>19 79</sup> Complete blood count with differential, should be evaluated at presentation and may be monitored as a marker for disease activity in patients with type I interferonopathies.

### *Ophthalmologic manifestations*

Patients with type I interferonopathies can develop different types of ophthalmologic manifestations. While patients with CANDLE/PRAAS can present with keratitis and/or episcleritis,<sup>2 18 51</sup> patients with SAVI and AGS can develop glaucoma.<sup>8 54 76</sup> Retinopathy has been described in AGS and SAVI but it remains unclear whether this occurs in the context of secondary mutations.<sup>89</sup>

### *Cardiac manifestations*



Patients with AGS, especially those with mutations in *TREX1*, are prone to develop infantile-onset hypertrophic cardiomyopathy.<sup>31 34</sup> There is an important risk of cardiac valve calcification in disease related to mutations in *IFIH1* and *ADAR*.<sup>90</sup>

Other considerations

#### *Immunodeficiency work up*

Patients with known type I interferonopathies may have some degree of immunodeficiency, either due to chronic disease and cytopenias or due to treatment with immunosuppressants.<sup>91</sup> Early manifestations may overlap with non-type I interferonopathy immunodeficiencies. Therefore, a basic immunologic work-up should be considered even in the context of a confirmed diagnosis. The work up should include a history of infections and assessment of lymphocyte subsets and immunoglobulin levels, as a minimum.<sup>1 12 92</sup>

Infections in patients with CANDLE/PRAAS can be associated with the development of macrophage activation syndrome (MAS). Opportunistic infections in patients with other CANDLE mutations or SAVI and AGS are rare, although pneumocystis infection has been reported in a SAVI patient who was not on any immunosuppressive treatment.<sup>88</sup> Furthermore, defects in maturation of CD8+ cells are identified in CANDLE patients,<sup>2 93</sup> and in some SAVI patients<sup>8 57 88</sup> severe infections are reported in two patients with *POMP* mutations,<sup>93</sup> which may be modified by additional genetic variants.

**Points to consider 9-12: Treatment focus on optimizing inflammatory disease control**

The goal of treatment is the control of the systemic and organ-specific disease manifestations, and to manage complications of existing organ damage that are consequences of untreated disease.

Pharmacologic treatment with Janus Kinase inhibitors (JAKI), particularly baricitinib, is widely used to treat patients with type I interferonopathies.<sup>1 94-97</sup> The JAKI are reported to be beneficial in controlling inflammatory symptoms and in preventing progression of end organ damage. Specifically, treatment with baricitinib resulted in a significantly lower daily diary score as well as significant reduction in glucocorticoid use in patients with type I interferonopathies in different open label trials.<sup>1 94</sup> In the study by Sanchez et al., none of the patients had achieved remission before initiating baricitinib treatment, and 50% of the CANDLE/PRAAS patients achieved lasting remission with no clinical symptoms, normalization of inflammatory markers on baricitinib, all discontinued glucocorticoids. In addition, patients with CANDLE had improvement in myositis and cytopenias (hemoglobin, lymphocyte, and platelets). Moreover, significant clinical improvement, including fewer vasculitis flares, prevention of skin involvement/progression of spontaneous amputations/the development of gangrene, and stabilization of ILD by preserving pulmonary function, was achieved in patients with SAVI.<sup>1</sup> However, to date, no SAVI patient treated with JAKI achieved complete remission. Furthermore, JAKI reduce IFN- $\alpha$  mediated STAT-1 phosphorylation in a dose dependent manner in interferonopathy patients<sup>26 56</sup> thus demonstrating an in vivo effect of the JAKI on type-1 IFN signaling. The JAKI, ruxolitinib and tofacitinib, are also reported as potential treatment options.<sup>44 56 59 97</sup> Population pharmacokinetics and pharmacodynamic analyses in children treated with baricitinib showed a substantially shorter half-life in pediatric than in adult populations requiring more frequent dosing, and led to a proposed weight- and estimated glomerular filtration rate-based dosing regimen to guide dose adjustments

in the growing child.<sup>26,17</sup> Doses of JAKI used to treat these conditions that were published are summarized in supplementary table 5. A beneficial effect of JAKI inflammatory disease manifestations is also observed in patients with AGS, including in an open label trial. The treatment led to decrease in interferon signaling genes (ISG) expression scores and improvement of AGS-related symptoms, including neurologic disability, crying, sleep disturbances, irritability, seizures, fever, and skin inflammation of the trunk, arms, and legs.<sup>94-96</sup> In all instances, pre-existing organ damage is irreparable (i.e., the neurologic manifestations) stressing the need for early treatment. In patients with AGS, treatment with HIV-1 reverse-transcriptase inhibitors reduced IFN scores, however, clinical benefit was not demonstrated<sup>98</sup> and thus it is unclear if these drugs can be recommended.

Viral reactivation including BK viral reactivation have been reported in type I interferonopathy patients treated with JAKI.<sup>1 59</sup> BK polyomavirus reactivation caused by therapeutic immunosuppression a commonly reported complication in renal transplant patients that can result in nephropathy and renal allograft loss. There is no proven treatment for BK nephropathy and management is limited to early detection and to controlling BK viral load by reducing the dose of immunosuppressive medications.<sup>99 100</sup> Monitoring for BK viral load in blood and urine and renal function prior to initiation of JAKI, at baseline, and then routinely at each visit is recommended.

Other viral reactivations, such as herpes, are reported in CANDLE/PRAAS and SAVI;<sup>1</sup> however, there are insufficient data to routinely recommend anti-viral drug prophylaxis for patients with CANDLE/PRAAS and SAVI treated with JAKI. Similarly, in AGS, viral prophylaxis for patients on JAKI is not currently recommended.

Finally, the data from an open label trial indicated that AGS patients who are receiving baricitinib should be monitored closely for thrombocytosis, leukopenia and infection, especially

those with underlying thrombotic risk factors or those who are receiving systemic glucocorticoids or immunosuppressive regimens,<sup>94</sup> while no such events were reported in two other reports.<sup>95 96</sup>

Glucocorticoids are generally considered useful in CANDLE/PRAAS and SAVI patients with systemic inflammation, although their use is limited by toxicity.<sup>1</sup> When used for a prolonged time, glucocorticoids cause serious side effects including growth arrest, truncal obesity, hypertension, glucose intolerance, and osteopenia.<sup>101</sup> Therefore the lowest possible dose of glucocorticoids should be targeted for disease control.

There is generally no role for chronic glucocorticoids in AGS, as glucocorticoids do not improve the long-term neurological features nor outcome of AGS. However, short courses of glucocorticoids to treat acute CNS and non-central nervous system (non-CNS) inflammatory manifestations, such as cytopenias and hepatitis, may be beneficial.

**Points to consider 13-17: Long-term monitoring and management focus on assessing inflammatory organ manifestations, minimizing treatment related toxicities, and encouraging general health measures, including vaccines, and fostering of self-management skills and medical decision-making**

A multidisciplinary team approach to regular clinical follow-up is recommended, and may include access to medical subspecialists including a rheumatologist, geneticist, neurologist, ophthalmologist, pulmonologist, cardiologist, hepatologist, gastroenterologist, hematologist, immunologist, dermatologist, endocrinologist, nephrologist, and access to supportive services including a physiatrist, wound care specialist, psychologist, bone health specialist, physical therapist, dental/oral surgeon, dietitian, psychiatrist, rehabilitation care, orthopedic care, and social support services. With current treatment strategies the ultimate treatment goal in inflammatory diseases, namely inflammatory remission, can only be achieved in a subset of patients. Remission

is mainly described in patients with CANDLE.<sup>1</sup> The current treatment goal is therefore to reduce systemic and organ inflammation and to prevent or limit the development or progression of organ injury/damage. This requires treatment adjustments and close monitoring of disease progression. Table 3 provides general and disease specific guidance for the monitoring of disease activity and assessment of organ damage. The monitoring should include a. assessment of the level of systemic inflammation, and of growth and sexual development, b. the assessment of general and disease-specific clinical signs and symptoms including the use of validated instruments when available,<sup>1</sup><sup>22 23</sup> c. monitoring of disease-specific organ manifestations and d. monitoring of the development of autoimmune features, cytopenias, treatment related complications and infections (immunodeficiencies). Preliminary guidance regarding the monitoring of JAKI treatment (Table 3) are provided but may need to be adjusted as experience with treatment of interferonopathies grows.

<b>Table 3 Evaluation of inflammatory disease manifestations and organ involvement with proposed interval monitoring</b>		<b>Follow-up frequency*</b>
<b>A. Monitoring of systemic inflammation and development</b>		
ESR, CRP, CBC with differential (cytopenias), IFN signature when available		At each visit*
Urinalysis (proteinuria, renal disease)		At each visit*
Renal ultrasound		To consider at baseline
Hepatosplenomegaly and lymphadenopathy		At each visit*
Height and weight		At each visit*
DEXA scan** (BMD)		As clinically indicated
Sexual development		As clinically indicated
<b>B. Monitoring of clinical disease signs and symptoms</b>		
<b>CANDLE/PRAAS</b>		
Fever, rash, progressive lipodystrophy, headache, musculoskeletal symptoms (joint pain, contractures, weakness), shortness of breath, weight changes, developmental assessment, fatigue		At each visit*
<b>SAVI</b>		

	Fever, rash, peripheral acral vasculitis and dystrophic changes, respiratory symptoms (shortness of breath, tachypnea, digital clubbing), fatigue	At each visit*
<b>AGS</b>		
	Developmental assessment, changes in neurologic tone affecting joint integrity, skin findings, musculoskeletal findings, clinical evidence of cytopenias, endocrine disturbance, ocular abnormalities, or cardiomyopathy	At each visit*
<b>C. Monitoring of organ manifestations</b>		
<b>CANDLE/PRAAS</b>		
<b>Skin disease</b>	Skin exam, assessment of lipodystrophy	Every 3-6 months till stable then every 6-12 months
	Lesional skin biopsy (neutrophilic panniculitis)	Baseline only
<b>Musculoskeletal disease</b>	Arthritis, contractures, weakness CK, aldolase, LDH for myositis	Every 6-12 months
<b>Endocrine, metabolic disease**</b>	Metabolic syndrome Lipid profile (dyslipidemia), fasting glucose, Hemoglobin A1C, serum insulin (insulin resistance) BP measurement (systemic hypertension)	Every 12-36 months depending on symptoms. At each visit*
		At each visit*
<b>Hepatic disease**</b>	ALT, AST, GGT, liver elastography, or screening for hepatic steatosis with the best available method	Every 6-12 months
<b>Pulmonary arterial hypertension**</b>	Echocardiography Cardiology and/or pulmonology referral if signs of PAH	Every 6-12 months, if PAH then as clinically indicated
<b>CNS disease**</b>	Lumbar puncture (if headaches), Brain MRI	Every 12-36 months depending on symptoms
<b>Eye disease**</b>	Scleritis, episcleritis, keratitis	Yearly or based on clinical need
<b>Dental disease</b>	Tooth abnormalities (tooth agenesis, hypodontia), delayed tooth eruption	Yearly or based on clinical need
<b>SAVI</b>		
<b>Skin disease</b>	Wound care (including wound culture as necessary)	As needed
<b>Pulmonary disease**</b>	Low radiation chest CT PFTs Pulmonology referral if signs of ILD	At baseline and then as needed Every 3-6 months As needed
<b>AGS</b>		
<b>Neurologic damage/progression**</b>	Brain MRI (cerebral white and grey matter changes) MRI/MRA in patients with <i>SAMHDI</i> associated AGS (intracerebral vasculitis) Electroencephalogram (epilepsy) Muscle MRI or ultrasound (myositis)	At baseline and then as needed  Yearly  As needed As needed
<b>Hepatic disease**</b>	ALT, AST, GGT, bilirubin total and direct, albumin, and INR (autoimmune hepatitis)	Every 6-12 months
<b>Endocrinopathies</b>	TSH (hypothyroidism) GH testing and glucose tolerance test	Yearly As needed based on symptoms
<b>Renal disease</b>	Urinalysis	Every 6-12 months
<b>Eye disease**</b>	Ophthalmologic evaluation (glaucoma)	Yearly
<b>Cardiorespiratory</b>	Echocardiogram (cardiomyopathy and PAH)	Every 1-2 years
<b>Scoliosis, hip dislocation**</b>	Hip X-rays and spine screening in non-ambulatory patients (hip dislocation)	Every 6-12 months

<b>D. Monitoring of autoimmunity, cytopenias, immunodeficiency, and JAK inhibitor related complications</b>		
<b>Autoimmunity and cytopenias and immunodeficiency</b>	Screening for autoimmunity (autoantibodies as indicated), CBC with differential (screening for anemia, thrombocytopenia, leukopenias) History of infections, lymphocyte subsets, immunoglobulin levels. Consider immunology or hematology referral	Every 6-12 months and when indicated  At baseline and then every 3-6 months
<b>Infections</b>	Clinical history, viral reactivation (on JAK inhibitors), opportunistic infections	At each visit
<b>JAK inhibitor monitoring</b>	CBC with differential, LFTs, urinalysis, renal function, creatinine clearance, BK viral loads in urine and blood, urine beta 2 microglobulin	At each visit

\*The visit frequency is set according to clinical need and the patient’s disease activity. If there is no active disease, then patients should be followed every 3 months to assess disease activity and monitor drug toxicity.

\*\*Requires subspecialty evaluation

AGS, Aicardi-Goutières Syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMD, bone mineral density; BP, blood pressure; CANDLE/PRAAS, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome; CBC, complete blood count; CK, creatinine kinase; CRP, C-reactive protein; CT, computed tomography; DEXA, dual energy X-ray absorptiometry; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transferase; GH, growth hormone; IFN, interferon; ILD, interstitial lung disease; INR, international normalized ratio; JAK: janus kinase; LDH, lactate dehydrogenase; LFTs, liver function tests; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; PAH, pulmonary arterial hypertension; PFTs, pulmonary function tests; SAVI, STING-Associated vasculopathy with onset in Infancy; TSH, thyroid stimulating hormone.

All patients should be evaluated at each visit for the presence of disease-specific symptoms and presence of systemic inflammation (table 3).

Chronic inflammation and chronic glucocorticoid treatment negatively affect bone health, (e.g., osteoporosis), growth (stunting) and development.<sup>1</sup> These parameters should be monitored regularly, as well as cardiac (e.g., hypertension) and ophthalmologic complications of chronic glucocorticoid use.

Patients with CANDLE/PRAAS should also be monitored for headaches, skin and musculoskeletal disease, development of metabolic syndrome (hypertension, hyperglycemia, and hepatic steatosis) and for development of primary pulmonary hypertension. Pulmonary hypertension can be insidious in onset. Although ILD is rare, it should be screened for at baseline and monitored as indicated by PFTs and low radiation chest CT. Ophthalmologic and dental

assessment may be required in patients with eye inflammation and hypodontia and tooth eruption problems.<sup>1 2 5 9 18 36 37 39 51</sup>

Patients with SAVI may require wound care (including wound culture as necessary), and close assessment of ILD and the development of secondary pulmonary hypertension. Patients should be screened for systemic hypertension, otolaryngology, ophthalmology, and dental disease at baseline and be followed as indicated. Patients should be instructed in self-care, including keeping peripheries warm, and in emergency management of acute ischemic digits (e.g., with – but not limited to – intravenous fluids, pentoxifylline, or intravenous vasodilators), prompt use of antibiotics if infection is suspected, and meticulous wound care.<sup>1 8 102</sup>

Patients with AGS are monitored for progression of neurologic disease including gross and fine motor function and cognitive function using validated scales when available.<sup>22 23</sup> Patients with *SAMHDI* mutations require yearly MRI and MR angiography studies to screen for intracerebral artery disease (e.g., Moyamoya).<sup>49 74 77</sup> Patients should be monitored for the development of systemic hypertension, pulmonary hypertension and cardiomyopathy.<sup>78</sup> Other complications include autoimmune hepatitis<sup>25 82</sup> and autoimmune endocrinopathies, most frequently hypothyroidism.<sup>34</sup> Other manifestations that can develop insidiously include glaucoma and epilepsy, and should be monitored as clinically indicated.<sup>76 103</sup> Neurologic tone abnormalities in non-ambulatory patients can lead to joint dislocation and scoliosis and should be monitored. Families should be instructed in prevention of skin complications, physical therapy, management of disturbed sleep-wake patterns and irritability commonly seen in AGS. Families can also participate in home stretching programs, and appropriate positioning of children with tone abnormalities.



Antinuclear antibodies (ANA) are seen in up to 62.5% of SAVI patients<sup>8</sup> and in up to 23% of AGS patients<sup>62</sup>, but are less frequent in CANDLE patients. Antineutrophil cytoplasmic antibodies (ANCA) are, intermittently, elevated in up to 71% of SAVI patients and 18 % of AGS patients.<sup>8 62</sup> Moreover, antiphospholipid antibodies are present in patients with CANDLE/PRAAS, SAVI and AGS<sup>1 7 62</sup>; and RF positivity is reported in patients with SAVI (see above). Urinalysis for kidney dysfunction and screening for autoimmunity based on the disease symptoms are recommended as kidney disease is reported mostly in patients with AGS<sup>50 62 79</sup> and SAVI.<sup>8 104 105</sup> Renal pathology prior to treatment with JAKI should be assessed by a baseline renal ultrasound and urine protein/creatinine ratio (or albumin/creatinine ratio).

All patients and families should have access to formal genetic counselling and may require social and other support. Supportive care, including adaptive equipment (e.g., orthoses, walkers, wheelchairs, seating equipment, etc.), may be required.

#### Treatment during infections including COVID-19

Disease flares and progression can occur if immunosuppressive treatment is held<sup>106</sup> and disease can flare in the context of an infection. Thus, any patient who develops an acute infection (or other complications) may require adjustment of immunosuppressive treatment (and/or institution of other supportive treatment), which should be conducted only under expert supervision. In line with these suggestions, recently published ACR guidance recommends continuing or initiating immunosuppressants when indicated in patients with pediatric rheumatic diseases in the context of exposure to SARS-CoV-2 or if experiencing asymptomatic SARS-CoV-2 infection. Immunosuppressants may be temporarily delayed or withheld if a patient has symptomatic COVID-19.<sup>107</sup>

## Vaccination

Whether vaccination may trigger disease flares in interferonopathies is an important and currently unanswered question. There are no data suggesting that patients with CANDLE/PRAAS and SAVI develop disease flares to routine childhood vaccinations and the Task Force therefore recommended compliance with local regulations when patients are not treated with immunosuppressive treatments or glucocorticoids. No such consensus was achieved for AGS: the safety of vaccines in this population is not fully evaluated, and anecdotal reports of vaccine induced neurological regression were concerns debated by the Task Force. No specific recommendation on vaccination for AGS was therefore possible. In line with general EULAR guidance, the Task Force recommends avoiding live vaccines in patients with CANDLE/PRAAS, SAVI, and AGS while on treatment with JAKI or other immunosuppressive medications.<sup>108</sup>

Ribonucleic acid (RNA) based SARS-Cov-2 vaccines are not live vaccines, suggesting that they may be safe for immunosuppressed patients. Whether vaccines against COVID-19 have the potential to provoke a disease flare is unknown, theoretical concerns about disease flare in type I interferonopathies caused by RNA vaccines exist. There are currently no data, to back specific recommendations.

## CONCLUSION

The aim of these points to consider is to address the unmet need to provide guidance for healthcare professionals involved in the care of patients with the recently characterized type I interferonopathies, CANDLE/PRAAS, SAVI and AGS. A lack of high-level evidence is a limitation to these points to consider and reflect the challenges of studying novel, ultra-rare

diseases. To address these challenges the Task Force generated guidance statements based on results from a thorough SLR and on specialists'/experts' opinions where evidence was lacking or was insufficient. The Task Force included various specialists with broad expertise in relevant clinical areas and representing different regions, disease interests, and practice environments.

Important areas of future research are outlined in table 4. The cost and availability of genetic testing, interferon signature assays, and JAKI treatment are substantial barriers that currently prevent optimized care for patients with interferonopathies. Furthermore, patients with the autoinflammatory interferonopathies CANDLE/PRAAS, SAVI, and AGS live in many different countries and are managed in different healthcare systems. These points to consider address the multiple challenges of managing patients with these ultrarare diseases, by providing guidance on improving clinical recognition, support for decision-making on genetic testing as well as treatment and long-term management. These points to consider were developed to increase awareness of these diseases, and to standardize the level of care by characterizing the diagnostic and therapeutic tools that can improve care.

<b>Table 4 Research agenda</b>
To define autoinflammatory disease outcomes, including: <ul style="list-style-type: none"> <li>Develop validated remission criteria for each disease including patient reported outcome measures.</li> <li>Develop minimal disease activity criteria.</li> <li>Validate identify sensitive biomarkers of progression of organ disease (including CNS).</li> </ul>
To further assess efficacy of Janus kinase inhibitors (JAKI) and other Type I IFN targeted therapies.
To assess long-term safety with treatment of JAKI. <ul style="list-style-type: none"> <li>Assess long-term effect of chronic BK viral reactivation.</li> <li>Recommend monitoring guidance including frequency of BK viral loads measurements and management of BK viremia.</li> </ul>
To assess requirement of viral prophylaxis on JAKI.
To identify novel therapeutic targets and better treatments.
To validate an interferon signature to diagnose and monitor patients (e.g., number of interferon response genes to include, sensitivity and specificity of score).
To evaluate the effect of vaccination in triggering or exacerbating disease activity in patients with type I interferonopathies while on or off treatments with immunosuppressive medications and/or glucocorticoids.
To identify new genetic causes for interferonopathies

CNS, central nervous system.

### **Acknowledgements:**

The Task Force gratefully thanks the librarian Darren Hamilton (London Health Sciences Center, London, Ontario, Canada) for his contribution to the systematic literature search, Brian Feldman, Hayyah Clairman and Natasha Naraidoo for their support of conducting the Delphi questionnaires using the Redcap platform and the European Alliance of Rheumatology Associations and the American College of Rheumatology for financial and logistical support.

This project is part of a series of “points to consider” consensus efforts to standardize the diagnosis, treatment, and long-term monitoring of patients with the 3 major groups of known autoinflammatory diseases including a. the IL-1 mediated diseases CAPS, TRAPS, MKD and DIRA, b. the autoinflammatory interferonopathies CANDLE, SAVI and AGS and c. the on early diagnosis, treatment, and long-term monitoring of inflammatory conditions with the potential progression to HLH/MAS.

This research was supported in part by the intramural research program of the NIH institutes, NIAID (KCG, RGM), NHGRI and NIAMS and by the Deutsche Forschungsgemeinschaft, grant CRC237 369799452/B21 to M.L.-K. We would like to acknowledge and are grateful for the generous and invaluable financial and organizational support from the Autoinflammatory Alliance and the systemic JIA foundation.

The Autoinflammatory Alliance substantially contributed to an international meeting and workgroup organization in August 2019 that developed the outline of the points to consider project. The funds for this preceding international meeting were largely due to patient fundraisers, online fundraising and the work of countless volunteers who made this project possible.

Contributions

All authors contributed to the formulation of the points to consider. In details, the steering committee of the Task Force (RGM, PB, AV, BF, ED) defined the research questions for the SLR. A systematic literature review was conducted by KCG, MR, LL with support from a librarian and epidemiologist (DH and DP) under supervision of a senior methodologist (ED). KCG, LL, MR extracted the data. RGM, PB and AV synthesized the results from SLR and Delphi questionnaires and generated draft statements. The manuscript was drafted by KCG, LL and MR and revised by RGM, PB, AV, ED and BF. DA oversaw the proceedings and provided advice of this points to consider project as EULAR methodologist. All other authors participated in the taskforce meetings, in two pre-meeting Delphi questionnaires, suggested and agreed upon the research questions, read the final statements prior to the manuscript, discussed results and made contributions to the text. All authors approved the final version of the manuscript.

### Funding

This work was funded by European Alliance of Rheumatology Associations/American College of Rheumatology (CLI120).

### Competing Interest

EF: received NIH Grant “Clinical Outcomes in Aicardi Goutières Syndrome” (Grant number 5U01NS106845-02) and participated in an advisory board of Biogen. EH: Spouse employed by Eli Lilly and received stock options in 2019 and 2020. SO1: NIH Grant “Clinical Outcomes in Aicardi Goutières Syndrome” (Grant number 5U01NS106845-02) and participated in advisory board of Biogen. CP: received consulting and lecture fees from Novartis. BF: is associate editor of Arthritis and Rheumatology and member of the ACR guidance document committee. AV:

received grant support from Eli Lilly. PB: received grants from Roche and consulting and lecture fees and travel support from Roche, SOBI and Novartis. RGM: received study support under government CRADAs from Eli Lilly, IFM and SOBI. The consensus meetings were sponsored as EULAR /ACR projects.

Patient and public involvement: Patients and/or the public were involved in the design, conduct, reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review not commissioned, externally peer reviewed.

Data availability statement: All data relevant to the study are included in the article or uploaded as supplementary information.

## REFERENCES

1. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. *J Clin Invest* 2018;128(7):3041-52. doi: 10.1172/JCI98814 [published Online First: 2018/04/13]
2. Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLER/PRAAS patients promote type I IFN production. *J Clin Invest* 2015;125(11):4196-211. doi: 10.1172/JCI81260 [published Online First: 2015/11/03]
3. Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. *Nat Rev Immunol* 2015;15(7):429-40. doi: 10.1038/nri3850 [published Online First: 2015/06/09]
4. Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLER, SAVI with AGS, Monogenic Lupus. *J Mol Med (Berl)* 2016;94(10):1111-27. doi: 10.1007/s00109-016-1465-5 [published Online First: 2016/09/30]
5. Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. *Proc Natl Acad Sci U S A* 2011;108(36):14914-9. doi: 10.1073/pnas.1106015108 [published Online First: 2011/08/20]

6. Piccoli C, Bronner N, Gavazzi F, et al. Late-Onset Aicardi-Goutieres Syndrome: A Characterization of Presenting Clinical Features. *Pediatr Neurol* 2021;115:1-6. doi: 10.1016/j.pediatrneurol.2020.10.012 [published Online First: 2020/12/12]
7. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. *N Engl J Med* 2014;371(6):507-18. doi: 10.1056/NEJMoa1312625 [published Online First: 2014/07/17]
8. Fremond ML, Hadchouel A, Berteloot L, et al. Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. *J Allergy Clin Immunol Pract* 2021;9(2):803-18 e11. doi: 10.1016/j.jaip.2020.11.007 [published Online First: 2020/11/21]
9. Garg A, Hernandez MD, Sousa AB, et al. An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. *J Clin Endocrinol Metab* 2010;95(9):E58-63. doi: 10.1210/jc.2010-0488 [published Online First: 2010/06/11]
10. Li J, An S, Du Z. Familial Interstitial Lung Disease Caused by Mutation of the STING1 Gene. *Front Pediatr* 2020;8:543. doi: 10.3389/fped.2020.00543 [published Online First: 2020/10/06]
11. Stellitano LA, Winstone AM, van der Knaap MS, et al. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. *Developmental Medicine and Child Neurology* 2016;58(7):680-89.
12. de Jesus AA, Hou Y, Brooks S, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. *J Clin Invest* 2020;130(4):1669-82. doi: 10.1172/jci129301 [published Online First: 2019/12/25]
13. Kim H, de Jesus AA, Brooks SR, et al. Development of a Validated Interferon Score Using NanoString Technology. *J Interferon Cytokine Res* 2018;38(4):171-85. doi: 10.1089/jir.2017.0127 [published Online First: 2018/04/12]
14. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis* 2015;74(1):8-13. doi: 10.1136/annrheumdis-2014-206350 [published Online First: 2014/09/28]
15. Niederberger M, Spranger J. Delphi Technique in Health Sciences: A Map. *Front Public Health* 2020;8:457. doi: 10.3389/fpubh.2020.00457 [published Online First: 2020/10/20]
16. OCEBM Levels of Evidence Working Group. Oxford centre for evidence-based medicine – levels of evidence (March 2009). Available: <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/> [Accessed 18 March 2021]. [
17. Fleiss JL. Statistical methods for rates and proportions. 2nd ed: New York: Wiley 1981:218.
18. Liu Y, Ramot Y, Torrello A, et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. *Arthritis Rheum* 2012;64(3):895-907. doi: 10.1002/art.33368 [published Online First: 2011/09/29]
19. Crow YJ, Jackson AP, Roberts E, et al. Aicardi-Goutieres syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. *American Journal of Human Genetics* 2000;67(1):213-21.

20. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. *Rheumatology (Oxford)* 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431 [published Online First: 2017/01/27]
21. Crow YJ, Shetty J, Livingston JH. Treatments in Aicardi-Goutieres syndrome. *Dev Med Child Neurol* 2020;62(1):42-47. doi: 10.1111/dmcn.14268 [published Online First: 2019/06/09]
22. Adang L, Gavazzi F, De Simone M, et al. Developmental Outcomes of Aicardi Goutieres Syndrome. *J Child Neurol* 2020;35(1):7-16. doi: 10.1177/0883073819870944 [published Online First: 2019/09/29]
23. Adang LA, Gavazzi F, Jawad AF, et al. Development of a neurologic severity scale for Aicardi Goutieres Syndrome. *Mol Genet Metab* 2020;130(2):153-60. doi: 10.1016/j.ymgme.2020.03.008 [published Online First: 2020/04/14]
24. Torrelo A. CANDLE Syndrome As a Paradigm of Proteasome-Related Autoinflammation. *Front Immunol* 2017;8:927. doi: 10.3389/fimmu.2017.00927 [published Online First: 2017/08/30]
25. Lanzi G, Fazzi E, D'Arrigo S, et al. The natural history of Aicardi-Goutieres syndrome: Follow-up of 11 Italian patients. *Neurology* 2005;64(9):1621-24.
26. Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. *Clin Pharmacol Ther* 2018;104(2):364-73. doi: 10.1002/cpt.936 [published Online First: 2017/11/15]
27. Wang BX, Grover SA, Kannu P, et al. Interferon-Stimulated Gene Expression as a Preferred Biomarker for Disease Activity in Aicardi-Goutieres Syndrome. *Journal of Interferon and Cytokine Research* 2017;37(4):147-52.
28. Rice GI, Del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. *Nat Genet* 2014;46(5):503-09. doi: 10.1038/ng.2933 [published Online First: 2014/04/02]
29. Livingston JH, Lin JP, Dale RC, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. *J Med Genet* 2014;51(2):76-82. doi: 10.1136/jmedgenet-2013-102038 [published Online First: 2013/11/23]
30. Armangue T, Orsini JJ, Takanohashi A, et al. Neonatal detection of Aicardi Goutieres Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. *Mol Genet Metab* 2017;122(3):134-39. doi: 10.1016/j.ymgme.2017.07.006 [published Online First: 2017/07/26]
31. Garau J, Cavallera V, Valente M, et al. Molecular genetics and interferon signature in the italian aicardi goutieres syndrome cohort: Report of 12 new cases and literature review. *Journal of Clinical Medicine* 2019;8(5)
32. Omoyinmi E, Standing A, Keylock A, et al. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. *PLoS One* 2017;12(7):e0181874. doi: 10.1371/journal.pone.0181874 [published Online First: 2017/07/28]
33. Al Mutairi F, Alfadhel M, Nashabat M, et al. Phenotypic and Molecular Spectrum of Aicardi-Goutieres Syndrome: A Study of 24 Patients. *Pediatric Neurology* 2018;78:35-40.



34. Crow YJ, Chase DS, Lowenstein Schmidt J, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. *American Journal of Medical Genetics, Part A* 2015;167(2):296-312.
35. de Jesus AA, Brehm A, VanTries R, et al. Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4. *J Allergy Clin Immunol* 2019;143(5):1939-43 e8. doi: 10.1016/j.jaci.2018.12.1012 [published Online First: 2019/01/22]
36. Kitamura A, Maekawa Y, Uehara H, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. *J Clin Invest* 2011;121(10):4150-60. doi: 10.1172/JCI58414 [published Online First: 2011/09/02]
37. Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. *Am J Hum Genet* 2010;87(6):866-72. doi: 10.1016/j.ajhg.2010.10.031 [published Online First: 2010/12/07]
38. Sarrabay G, Mechin D, Salhi A, et al. PSMB10, the last immunoproteasome gene missing for PRAAS. *J Allergy Clin Immunol* 2020;145(3):1015-17 e6. doi: 10.1016/j.jaci.2019.11.024 [published Online First: 2019/11/30]
39. Ayaki T, Murata K, Kanazawa N, et al. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. *Neuropathol Appl Neurobiol* 2020;46(6):579-87. doi: 10.1111/nan.12614 [published Online First: 2020/03/08]
40. Sonmez HE, Karaaslan C, de Jesus AA, et al. A clinical score to guide in decision making for monogenic type I IFNopathies. *Pediatr Res* 2020;87(4):745-52. doi: 10.1038/s41390-019-0614-2 [published Online First: 2019/10/24]
41. Vanderver A, Prust M, Kadom N, et al. Early-Onset Aicardi-Goutieres Syndrome. *Journal of Child Neurology* 2015;30(10):1343-48.
42. Tonduti D, Izzo G, D'Arrigo S, et al. Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutieres syndrome: Diagnostic and disease-monitoring implications. *Molecular Genetics and Metabolism* 2019;126(4):489-94.
43. Clarke SLN, Robertson L, Rice GI, et al. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype. *Pediatr Rheumatol Online J* 2020;18(1):37. doi: 10.1186/s12969-020-00425-w [published Online First: 2020/05/14]
44. Konig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. *Ann Rheum Dis* 2017;76(2):468-72. doi: 10.1136/annrheumdis-2016-209841 [published Online First: 2016/08/28]
45. Jain A, Misra DP, Sharma A, et al. Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes. *Rheumatology international* 2018;38(1):13-24. doi: 10.1007/s00296-017-3839-6 [published Online First: 2017/10/17]
46. Jeremiah N, Neven B, Gentili M, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. *J Clin Invest* 2014;124(12):5516-20. doi: 10.1172/JCI79100 [published Online First: 2014/11/18]
47. Lin B, Berard R, Al Rasheed A, et al. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). *J Allergy Clin Immunol*

- 2020;146(5):1204-08 e6. doi: 10.1016/j.jaci.2020.06.032 [published Online First: 2020/07/17]
48. Uggenti C, Lepelley A, Depp M, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. *Nat Genet* 2020;52(12):1364-72. doi: 10.1038/s41588-020-00737-3 [published Online First: 2020/11/25]
49. Xin B, Jones S, Puffenberger EG, et al. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. *Proc Natl Acad Sci U S A* 2011;108(13):5372-7. doi: 10.1073/pnas.1014265108 [published Online First: 2011/03/16]
50. Ramantani G, Kohlhase J, Hertzberg C, et al. Expanding the phenotypic spectrum of lupus erythematosus in aicardi-goutieres syndrome. *Arthritis and Rheumatism* 2010;62(5):1469-77.
51. Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. *J Am Acad Dermatol* 2010;62(3):489-95. doi: 10.1016/j.jaad.2009.04.046 [published Online First: 2010/02/18]
52. Moreno Medinilla EE, Villagran Garcia M, Mora Ramirez MD, et al. Aicardi-Goutieres syndrome: Phenotypic and genetic spectrum in a series of three cases. *Anales de Pediatría* 2019;90(5):312-14.
53. Videira G, Malaquias MJ, Laranjinha I, et al. Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series. *Mov Disord Clin Pract* 2020;7(3):303-07. doi: 10.1002/mdc3.12903 [published Online First: 2020/04/08]
54. Abe J, Nakamura K, Nishikomori R, et al. A nationwide survey of Aicardi-Goutieres syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study. *Rheumatology (United Kingdom)* 2014;53(3):448-58.
55. Yarbrough K, Danko C, Krol A, et al. The importance of chilblains as a diagnostic clue for mild Aicardi-Goutieres syndrome. *American Journal of Medical Genetics, Part A* 2016;170(12):3308-12.
56. Fremont ML, Rodero MP, Jeremiah N, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. *J Allergy Clin Immunol* 2016;138(6):1752-55. doi: 10.1016/j.jaci.2016.07.015 [published Online First: 2016/08/25]
57. Keskitalo S, Haapaniemi E, Einarsdottir E, et al. Novel TMEM173 Mutation and the Role of Disease Modifying Alleles. *Front Immunol* 2019;10:2770. doi: 10.3389/fimmu.2019.02770 [published Online First: 2019/12/24]
58. Melki I, Rose Y, Uggenti C, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. *J Allergy Clin Immunol* 2017;140(2):543-52 e5. doi: 10.1016/j.jaci.2016.10.031 [published Online First: 2017/01/15]
59. Volpi S, Insalaco A, Caorsi R, et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. *J Clin Immunol* 2019;39(5):476-85. doi: 10.1007/s10875-019-00645-0 [published Online First: 2019/05/31]

60. Tang X, Xu H, Zhou C, et al. STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib. *J Clin Immunol* 2020;40(1):114-22. doi: 10.1007/s10875-019-00690-9 [published Online First: 2019/11/11]
61. Picard C, Thouvenin G, Kannengiesser C, et al. Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation). *Chest* 2016;150(3):e65-71. doi: 10.1016/j.chest.2016.02.682 [published Online First: 2016/09/11]
62. Cattalini M, Galli J, Andreoli L, et al. Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi-Goutieres Syndrome. *Journal of Clinical Immunology* 2016;36(7):693-99.
63. Kolivras A, Aeby A, Crow YJ, et al. Cutaneous histopathological findings of Aicardi-Goutieres syndrome, overlap with chilblain lupus. *J Cutan Pathol* 2008;35(8):774-8. doi: 10.1111/j.1600-0560.2007.00900.x [published Online First: 2008/04/22]
64. Crow YJ, Zaki MS, Abdel-Hamid MS, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. *Neuropediatrics* 2014;45(6):386-91.
65. Izzotti A, Pulliero A, Orcesi S, et al. Interferon-related transcriptome alterations in the cerebrospinal fluid cells of aicardi-goutieres patients. *Brain Pathology* 2009;19(4):650-60.
66. La Piana R, Uggetti C, Roncarolo F, et al. Neuroradiologic patterns and novel imaging findings in Aicardi-Goutieres syndrome. *Neurology* 2016;86(1):28-35.
67. Salerno S, Granata C, Trapenese M, et al. Is MRI imaging in pediatric age totally safe? A critical reprisal. *Radiol Med* 2018;123(9):695-702. doi: 10.1007/s11547-018-0896-1 [published Online First: 2018/05/05]
68. Livingston JH, Stivaros S, Van Der Knaap MS, et al. Recognizable phenotypes associated with intracranial calcification. *Developmental Medicine and Child Neurology* 2013;55(1):46-57.
69. Abdel-Salam GMH, Zaki MS, Lebon P, et al. Aicardi-Goutieres syndrome: Clinical and neuroradiological findings of 10 new cases. *Acta Paediatrica, International Journal of Paediatrics* 2004;93(7):929-36.
70. Uggetti C, La Piana R, Orcesi S, et al. Aicardi-Goutieres syndrome: Neuroradiologic findings and follow-up. *American Journal of Neuroradiology* 2009;30(10):1971-76.
71. Uyur-Yalcin E, Maras-Genc H, Kara B. Clinical and neuroradiologic variability of Aicardi-Goutieres syndrome: Two siblings with RNASEH2C mutation and a boy with TREX1 mutation. *Turkish Journal of Pediatrics* 2015;57(5):504-08.
72. Goutieres F, Aicardi J, Barth PG, et al. Aicardi-Goutieres syndrome: An update and results of interferon-alpha studies. *Annals of Neurology* 1998;44(6):900-07.
73. Lanzi G, Fazzi E, D'Arrigo S. Aicardi-Goutieres syndrome: A description of 21 new cases and a comparison with the literature. *European Journal of Paediatric Neurology* 2002;6(SUPPL. 1):A9-A22.
74. Ramesh V, Bernardi B, Stafa A, et al. Intracerebral large artery disease in Aicardi-Goutieres syndrome implicates SAMHD1 in vascular homeostasis. *Developmental Medicine and Child Neurology* 2010;52(8):725-32.
75. Rossler L, Ludwig-Seibold C, Thiels C, et al. Aicardi-Goutieres syndrome with emphasis on sonographic features in infancy. *Pediatric Radiology* 2012;42(8):932-40.

76. Crow YJ, Massey RF, Innes JR, et al. Congenital glaucoma and brain stem atrophy as features of Aicardi-Goutieres syndrome. *Am J Med Genet A* 2004;129a(3):303-7. doi: 10.1002/ajmg.a.30250 [published Online First: 2004/08/25]
77. Thiele H, du Moulin M, Barczyk K, et al. Cerebral arterial stenoses and stroke: novel features of Aicardi-Goutieres syndrome caused by the Arg164X mutation in SAMHD1 are associated with altered cytokine expression. *Hum Mutat* 2010;31(11):E1836-50. doi: 10.1002/humu.21357 [published Online First: 2010/09/16]
78. Adang LA, Frank DB, Gilani A, et al. Aicardi goutieres syndrome is associated with pulmonary hypertension. *Molecular Genetics and Metabolism* 2018;125(4):351-58.
79. Samanta D, Ramakrishnaiah R, Crary SE, et al. Multiple Autoimmune Disorders in Aicardi-Goutières Syndrome. *Pediatr Neurol* 2019;96:37-39. doi: 10.1016/j.pediatrneurol.2019.01.017 [published Online First: 2019/03/23]
80. Ishikawa T, Tamura E, Kasahara M, et al. Severe Liver Disorder Following Liver Transplantation in STING-Associated Vasculopathy with Onset in Infancy. *J Clin Immunol* 2021 doi: 10.1007/s10875-021-00977-w [published Online First: 2021/02/06]
81. Ford ES, Ajani UA, Mokdad AH, et al. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. *Diabetes Care* 2005;28(4):878-81. doi: 10.2337/diacare.28.4.878 [published Online First: 2005/03/29]
82. Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. *American Journal of Human Genetics* 2007;81(4):713-25.
83. Abe J, Izawa K, Nishikomori R, et al. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus. *Rheumatology (Oxford)* 2013;52(2):406-8. doi: 10.1093/rheumatology/kes181 [published Online First: 2012/07/26]
84. Hebbar M, Kanthi A, Shrikiran A, et al. p.Arg69Trp in RNASEH2C is a founder variant in three Indian families with Aicardi-Goutieres syndrome. *American Journal of Medical Genetics, Part A* 2018;176(1):156-60.
85. Tumiene B, Voisin N, Preiksaitiene E, et al. Inflammatory myopathy in a patient with Aicardi-Goutieres syndrome. *Eur J Med Genet* 2017;60(3):154-58. doi: 10.1016/j.ejmg.2016.12.004 [published Online First: 2017/01/17]
86. Dale RC, Gornall H, Singh-Grewal D, et al. Familial Aicardi-Goutieres syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures. *Am J Med Genet A* 2010;152A(4):938-42. doi: 10.1002/ajmg.a.33359 [published Online First: 2010/04/02]
87. Buers I, Rice GI, Crow YJ, et al. MDA5-Associated Neuroinflammation and the Singleton-Merten Syndrome: Two Faces of the Same Type I Interferonopathy Spectrum. *J Interferon Cytokine Res* 2017;37(5):214-19. doi: 10.1089/jir.2017.0004 [published Online First: 2017/05/06]
88. Saldanha RG, Balka KR, Davidson S, et al. A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy. *Front Immunol* 2018;9:1535. doi: 10.3389/fimmu.2018.01535 [published Online First: 2018/07/25]
89. Cooray S, Henderson R, Solebo AL, et al. Retinal vasculopathy in STING-Associated Vasculitis of Infancy (SAVI). *Rheumatology (Oxford)* 2021 doi: 10.1093/rheumatology/keab297 [published Online First: 2021/03/26]

90. Crow Y, Keshavan N, Barbet JP, et al. Cardiac valve involvement in ADAR-related type I interferonopathy. *J Med Genet* 2020;57(7):475-78. doi: 10.1136/jmedgenet-2019-106457 [published Online First: 2019/11/28]
91. Lee-Kirsch MA. The Type I Interferonopathies. *Annu Rev Med* 2017;68:297-315. doi: 10.1146/annurev-med-050715-104506 [published Online First: 2016/11/05]
92. Al-Mayouf SM, AlSaleem A, AlMutairi N, et al. Monogenic interferonopathies: Phenotypic and genotypic findings of CANDLE syndrome and its overlap with C1q deficient SLE. *Int J Rheum Dis* 2018;21(1):208-13. doi: 10.1111/1756-185X.13228 [published Online First: 2017/11/09]
93. Poli MC, Ebstein F, Nicholas SK, et al. Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome. *Am J Hum Genet* 2018;102(6):1126-42. doi: 10.1016/j.ajhg.2018.04.010 [published Online First: 2018/05/29]
94. Vanderver A, Adang L, Gavazzi F, et al. Janus Kinase Inhibition in the Aicardi-Goutieres Syndrome. *N Engl J Med* 2020;383(10):986-89. doi: 10.1056/NEJMc2001362 [published Online First: 2020/09/03]
95. Meesilpavikkai K, Dik WA, Schrijver B, et al. Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutieres Syndrome, a Type I Interferonopathy. *Arthritis and Rheumatology* 2019;71(5):829-31.
96. Zimmermann N, Wolf C, Schwenke R, et al. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation. *JAMA Dermatol* 2019;155(3):342-46. doi: 10.1001/jamadermatol.2018.5077 [published Online First: 2019/01/24]
97. Patel PN, Hunt R, Pettigrew ZJ, et al. Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib. *Pediatr Dermatol* 2021 doi: 10.1111/pde.14517 [published Online First: 2021/01/30]
98. Rice GI, Meyzer C, Bouazza N, et al. Reverse-Transcriptase Inhibitors in the Aicardi-Goutieres Syndrome. *N Engl J Med* 2018;379(23):2275-7. doi: 10.1056/NEJMc1810983 [published Online First: 2018/12/20]
99. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. *Kidney Int* 2010;77(4):299-311. doi: 10.1038/ki.2009.377 [published Online First: 2009/10/23]
100. Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. *Am J Transplant* 2004;4(12):2109-17. doi: 10.1111/j.1600-6143.2004.00629.x [published Online First: 2004/12/04]
101. Buchman AL. Side effects of corticosteroid therapy. *J Clin Gastroenterol* 2001;33(4):289-94. doi: 10.1097/00004836-200110000-00006 [published Online First: 2001/10/06]
102. Fremont ML, Crow YJ. STING-Mediated Lung Inflammation and Beyond. *J Clin Immunol* 2021;41(3):501-14. doi: 10.1007/s10875-021-00974-z [published Online First: 2021/02/04]
103. Ramantani G, Maillard LG, Bast T, et al. Epilepsy in Aicardi-Goutieres syndrome. *European Journal of Paediatric Neurology* 2014;18(1):30-37.

104. Ma M, Mazumder S, Kwak H, et al. Case Report: Acute Thrombotic Microangiopathy in a Patient with STING-Associated Vasculopathy with Onset in Infancy (SAVI). *J Clin Immunol* 2020;40(8):1111-15. doi: 10.1007/s10875-020-00850-2 [published Online First: 2020/08/30]
105. Abid Q, Best Rocha A, Larsen CP, et al. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI). *Am J Kidney Dis* 2020;75(2):287-90. doi: 10.1053/j.ajkd.2019.07.010 [published Online First: 2019/10/12]
106. Adang L, Goldbach-Mansky R, Vanderver A. JAK Inhibition in the Aicardi-Goutieres Syndrome. Reply. *N Engl J Med* 2020;383(22):2191-93. doi: 10.1056/NEJMc2031081 [published Online First: 2020/12/01]
107. Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. *Arthritis Rheumatol* 2020;72(11):1809-19. doi: 10.1002/art.41455 [published Online First: 2020/07/25]
108. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882 [published Online First: 2019/08/16]